LAURUS LABS LIMITED vs Mankind Pharma Limited

A side-by-side comparison of LAURUS LABS LIMITED (LAURUSLABS) and Mankind Pharma Limited (MANKIND) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Mankind Pharma Limited leads LAURUSLABS vs MANKIND on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

104.09
P/E ratio
54.10
15.99
P/B ratio
6.30
0.13%
Dividend yield
0.04%
₹16.46
EPS
₹46.34

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

18.30%
Return on equity
13.10%
18.00%
Return on capital
14.00%
26.00%
EBITDA margin
25.00%
13.06%
Net margin
13.57%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

4.09%
Revenue CAGR (3Y)
17.73%
3.92%
Profit CAGR (3Y)
13.94%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹92,414 Cr
Market cap
₹1.03L Cr
₹6,813 Cr
Revenue
₹14,278 Cr
₹890 Cr
Net profit
₹1,938 Cr
0.48
Debt / equity
0.39
LAURUS LABS LIMITED
  • + ["Company has been maintaining a healthy dividend payout of 19.0%"]
  • ["Stock is trading at 16.3 times its book value", "The company has delivered a poor sales growth of 7.19% over past five years.", "Company has a low return on equity of 10.1% over last 3 years.", "Company might be capitalizing the interest cost"]
Mankind Pharma Limited
  • + ["Company has reduced debt."]
  • ["Promoter holding has decreased over last 3 years: -3.87%"]
LAURUS LABS LIMITED full analysis Mankind Pharma Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.